The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | The latest developments in CAR-T and BiTE therapies for B-cell and mantle cell lymphoma
Andre Goy, MD, John Theurer Cancer Center, Hackensack, NJ, discusses some of the latest developments in CAR-T and bispecific T-cell engager (BiTE) therapies for the treatment of lymphoma presented at the ASCO 2022 Annual Meeting, including mantle cell lymphoma (MCL) and B-cell lymphoma (BCL). Real-world data on axicabtagene ciloleucel (axi-cel) demonstrated that race and ethnicity do not have an impact on response rates (RR), clinical benefit, and safety. A 3-year follow-up of the Phase III ZUMA-2 (NCT03391466) trial suggested that brexucabtagene autoleucel (brexu-cel) induces durable long-term responses with manageable safety and low late relapse potential in patients with relapsed/refractory (R/R) MCL. Data on CAR-engineered allogeneic gamma delta (γδ) T cells showed encouraging preliminary activity in adults with R/R BCL as well as a favorable safety profile. Dr Goy additionally mentions an NK cell engager targeting CD16 and CD30 in both solid and hematologic malignancies. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
